Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
Scientific News
The Switch That Might Tame The Most Aggressive Of Breast Cancers
Garvan researchers have found that so-called ‘triple-negative breast cancers’ are two distinct diseases that likely originate from different cell types. They have also found a gene that drives the aggressive disease, and hope to find a way to ‘switch it off’.
Gene Editing Technique Mastered In Mosquito That Transmits Deadly Diseases
Technique will help researchers learn more about the role of genes that are involved in mosquito propagation.
Honey Bees Use Multiple Genetic Pathways To Fight Infections
The findings may help scientists develop honey bee treatments that are tailored to specific types of infections.
Chemical Tag Marks Future microRNAs for Processing
New research reveals how cells sort out the loops meant to encode small RNAs.
Blood Test Could Help Bowel Cancer Patients Avoid Drug Side-Effects
Manchester researchers have provided early evidence to suggest that a blood test could be used to identify bowel cancer patients that may benefit from more intensive chemotherapy.
Bright New Hope for Beating Deadly Hereditary Stomach and Breast Cancers
Researchers use genomic screening to search for vulnerabilities in the cancer cells.
Novel Approach Gives Insights Into Tumor Development
Scientists used a powerful new technique to turn off all the genes in mouse lung cancer cells and test how they affect tumor growth and metastasis.
New Cyclotron Facility at UT Southwestern
Expands research opportunities and imaging capabilities for detecting, tracking cancer.
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
World-First Cancer Drugs Could Work In Larger Group Of Patients
A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumours with another type of genetic fault, a new study suggests.
Return
Therapeutic Targeting of Neuroendocrine Tumours Utilising microRNAs
Stan Sidhu, University of Sydney, speaking at Genomics Research Europe 2012
Date Posted: Friday, February 01, 2013
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Related Content

Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
Company will undertake a target discovery project for an undisclosed disease indication.
Tuesday, May 06, 2014
Cenix BioScience Joins EU FP7 Consortium for Discovery of miRNA Medicines
Company has joined an EU-funded consortium focused on the discovery of microRNA medicines in the area of cardiac and inflammatory metabolic diseases.
Wednesday, August 14, 2013
Cenix BioScience Expands Operations to U.S.
Company establishes new subsidiary named Cenix BioScience USA in Minnesota.
Friday, March 02, 2012
Cenix signs RNAi research agreement with SYGNIS
Cenix BioScience GmbH, announced it has signed a research agreement with SYGNIS Bioscience GmbH & Co. KG, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.
Thursday, November 17, 2011
Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery
Collaboration and Technology License Agreement to improve the in vivo applicability of siRNA-based experimentation, focusing on the further co-development of DARE™.
Thursday, May 05, 2011
Cenix BioScience Joins EU FP7 Consortium
Consortium focused on improving the in vivo use of siRNA technology in the area of respiratory and inflammatory diseases.
Wednesday, March 30, 2011
Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium
The new company accelerates the development of the company’s R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi.
Saturday, January 15, 2011
Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement
The new agreement calls for Cenix to complete three major projects applying same platform for RNAi-based research.
Friday, June 26, 2009
Cenix BioScience Signs Multi-Project Research Agreement with AstraZeneca
The agreement expands relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.
Tuesday, June 16, 2009
InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery
The research agreement comprises functional screens in human cell lines using InteRNA’s proprietary library of miRNAs.
Tuesday, November 18, 2008
 
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters